The name Gossamer Bio depicts the symbolism behind the gossamer thread, the fragile connection that binds all relationships in life. In our context, this is intended to highlight the importance of our relationships with patients in a healthcare system, employees, shareholders, providers and partners. We take these relationships seriously and aim to strengthen these connections continuously. Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to enhance the lives of people living with pulmonary hypertension.

Faheem Hasnain
Co-Founder, Chairman, and Chief Executive Officer

Richard Aranda, M.D.
Chief Medical Officer

Jeff Boerneke
General Counsel and Secretary

Matt Cravets
Senior Vice President, Biometrics

Bryan Giraudo
Chief Operating Officer & Chief Financial Officer

Lisa Nolan, Ph.D.
Managing Director and President, Gossamer Bio Ireland

Mario Orlando
Senior Vice President, Commercial New Product Planning

Caryn Peterson
Executive Vice President, Regulatory Affairs

Colin Rowlings, Ph.D.
Senior Vice President, CMC

Christian Waage
Executive Vice President, Technical Operations & Administration

Deanna Weber
Senior Vice President, Human Resources